Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
shaping cancer immunosurveillance and response to immunotherapy. Our understanding of …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Increased glucose metabolism and uptake are characteristic of many tumors and used
clinically to diagnose and monitor cancer progression. In addition to cancer cells, the tumor …

The tumor microenvironment (TME) is connected to immunotherapy responses, but it
remains unclear how cancer cells and host tissues differentially influence the immune …

Severe immune-related adverse events (irAEs) occur in up to 60% of patients with
melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Background Bladder cancer (BLCA) is the most common malignancy of the urinary tract. On
the other hand, disulfidptosis, a mechanism of disulfide stress-induced cell death, is closely …

Clinical immunotherapy of solid tumors elicits durable responses only in a minority of
patients, largely due to the highly immunosuppressive tumor microenvironment (TME) …

Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic
activity, have recently attracted attention as potential anticancer therapeutics. While NK cells …